We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+8.97%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
-$24.8M
(-0.89%)
Cap. Flow
-$295M
Cap. Flow
% of AUM
-10.7%
Top 10 Holdings %
Top 10 Hldgs %
47.94%
Holding
172
New
14
Increased
31
Reduced
25
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$27.4M |
| 2 |
SHPG
Shire pic
SHPG
|
+$25.4M |
| 3 |
Illumina
ILMN
|
+$22.1M |
| 4 |
MDVN
MEDIVATION, INC.
MDVN
|
+$19.9M |
| 5 |
HCA Healthcare
HCA
|
+$14.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$72.3M |
| 2 |
Alkermes
ALKS
|
+$45.9M |
| 3 |
AET
Aetna Inc
AET
|
+$36.3M |
| 4 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$23M |
| 5 |
AKRX
Akorn Inc
AKRX
|
+$22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.47% |
| 2 | Real Estate | 3.59% |
| 3 | Financials | 0% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$163B
| $236M | 8.55% |
2,331,231
+109,800
| +5% | +$11.4M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $205M | 7.44% |
1,713,634
| – | – |
|
3
Biogen
BIIB
$30.7B
| $138M | 5.01% |
450,533
-16,650
| -4% | -$4.78M |
|
4
Vertex Pharmaceuticals
VRTX
$122B
| $130M | 4.72% |
1,033,503
+23,600
| +2% | +$2.85M |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $128M | 4.64% |
409,586
+91,900
| +29% | +$27.4M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $121M | 4.41% |
636,805
| – | – |
|
7
Johnson & Johnson
JNJ
$617B
| $96.7M | 3.51% |
940,988
| – | – |
|
8
Incyte
INCY
$24.9B
| $95.5M | 3.46% |
880,461
| – | – |
|
9
Teva Pharmaceuticals
TEVA
$41.2B
| $87.6M | 3.18% |
1,334,237
-51,357
| -4% | -$3.17M |
|
10
Regeneron Pharmaceuticals
REGN
$77.4B
| $83.7M | 3.04% |
154,266
| – | – |
|
|
11
Illumina
ILMN
$31B
| $83.4M | 3.02% |
446,503
+136,724
| +44% | +$22.1M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.7B
| $62.5M | 2.26% |
596,145
+25,668
| +4% | +$2.68M |
|
13
Pfizer
PFE
$142B
| $58.2M | 2.11% |
1,899,615
| – | – |
|
14
Amgen
AMGN
$209B
| $52.2M | 1.89% |
321,640
| – | – |
|
15
UnitedHealth
UNH
$383B
| $48.1M | 1.75% |
409,100
+96,500
| +31% | +$11.3M |
|
|
16
Alkermes
ALKS
$8.39B
| $40.5M | 1.47% |
510,444
-655,374
| -56% | -$45.9M |
|
17
Merck
MRK
$321B
| $36M | 1.3% |
713,790
| – | – |
|
|
SHPG
18
DELISTED
Shire pic
SHPG
| $35.2M | 1.28% |
171,813
+122,300
| +247% | +$25.4M |
|
|
MDVN
19
DELISTED
MEDIVATION, INC.
MDVN
| $32.3M | 1.17% |
667,300
+461,900
| +225% | +$19.9M |
|
20
Agilent Technologies
A
$39.2B
| $30.5M | 1.1% |
728,650
+93,000
| +15% | +$3.6M |
|
|
21
HCA Healthcare
HCA
$85.7B
| $30.3M | 1.1% |
448,488
+205,300
| +84% | +$14.3M |
|
|
22
Viatris
VTRS
$20.7B
| $28.7M | 1.04% |
531,252
-1,504,405
| -74% | -$72.3M |
|
23
Humana
HUM
$44B
| $23.1M | 0.84% |
129,300
| – | – |
|
24
Acadia Pharmaceuticals
ACAD
$4.55B
| $22.7M | 0.82% |
637,500
+75,000
| +13% | +$2.64M |
|
25
Molina Healthcare
MOH
$10.2B
| $20.9M | 0.76% |
347,901
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q4 2015 Portfolio in Review
As of Q4 2015, Tekla Capital Management held 172 positions worth $2.76B, down 0.89% from $2.78B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Tekla Capital Management withdrew a net $295M in Q4 2015, closing 39 positions and reducing 25 holdings. Its most notable exit was Aetna Inc, an estimated $36.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 81% a quarter earlier, followed by Real Estate and Financials.
Against the trend, Tekla Capital Management opened a new position in Sanofi worth $13M.
- Tekla Capital Management's largest Q4 2015 buy was Sanofi: 305,000 shares worth $13M.
- Tekla Capital Management added most to Allergan plc in Q4 2015, an estimated $27.4M increase.
- Tekla Capital Management's biggest Q4 2015 reduction was Viatris, cutting an estimated $72.3M.
- Tekla Capital Management fully exited Aetna Inc in Q4 2015, selling an estimated $36.3M.
- Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q4 2015.
- Tekla Capital Management opened 14 new positions and closed 39 in Q4 2015.
- Tekla Capital Management's portfolio value fell 0.89% quarter-over-quarter to $2.76B.
Based on Tekla Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.